(NASDAQ: PCVX) Vaxcyte's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.2%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.65%.
Vaxcyte's earnings in 2026 is -$946,532,000.On average, 12 Wall Street analysts forecast PCVX's earnings for 2026 to be -$1,187,613,175, with the lowest PCVX earnings forecast at -$1,388,210,435, and the highest PCVX earnings forecast at -$943,061,261. On average, 12 Wall Street analysts forecast PCVX's earnings for 2027 to be -$985,340,902, with the lowest PCVX earnings forecast at -$1,623,116,584, and the highest PCVX earnings forecast at -$233,491,052.
In 2028, PCVX is forecast to generate -$943,465,575 in earnings, with the lowest earnings forecast at -$1,621,701,487 and the highest earnings forecast at -$712,602,561.